Clinical predictors for the prognosis of myasthenia gravis
Abstract Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-04-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12883-017-0857-7 |
| _version_ | 1817977722008240128 |
|---|---|
| author | Lili Wang Yun Zhang Maolin He |
| author_facet | Lili Wang Yun Zhang Maolin He |
| author_sort | Lili Wang |
| collection | DOAJ |
| description | Abstract Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. Methods Eighty three patients with myasthenia gravis were concluded in this study. Baseline characteristics were analyzed as predictors. Results Relapse of myasthenia gravis developed in 26 patients (34%). Generalization developed in 34 ocular myasthenia gravis patients (85%). Other autoimmune diseases were observed more commonly in relapsed myasthenia gravis (P = 0.012). Second generalization group contained more late onset patients (P = 0.021). Ocular myasthenia gravis patients with thymus hyperplasia progressed more rapidly than those with other thymus pathology (P = 0.027). Single onset symptom of ocular myasthenia gravis such as ptosis or diplopia predicted early progression than concurrence of ptosis and diplopia (P = 0.027). Treatment effect including glucocorticoid, pyridostigmine, thymectomy, IVIG, immunosuppressive drugs did not show significant difference between the relapsed and non-relapsed groups. The treatment outcome also showed no difference between the single OMG and second generalized groups. Conclusions Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months. |
| first_indexed | 2024-04-13T22:20:07Z |
| format | Article |
| id | doaj.art-7939a44c7c3d47038f346c1706c5391a |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-04-13T22:20:07Z |
| publishDate | 2017-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-7939a44c7c3d47038f346c1706c5391a2022-12-22T02:27:18ZengBMCBMC Neurology1471-23772017-04-011711610.1186/s12883-017-0857-7Clinical predictors for the prognosis of myasthenia gravisLili Wang0Yun Zhang1Maolin He2Department of Neurology, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Neurology, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Neurology, Beijing Shijitan Hospital, Capital Medical UniversityAbstract Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis. Methods Eighty three patients with myasthenia gravis were concluded in this study. Baseline characteristics were analyzed as predictors. Results Relapse of myasthenia gravis developed in 26 patients (34%). Generalization developed in 34 ocular myasthenia gravis patients (85%). Other autoimmune diseases were observed more commonly in relapsed myasthenia gravis (P = 0.012). Second generalization group contained more late onset patients (P = 0.021). Ocular myasthenia gravis patients with thymus hyperplasia progressed more rapidly than those with other thymus pathology (P = 0.027). Single onset symptom of ocular myasthenia gravis such as ptosis or diplopia predicted early progression than concurrence of ptosis and diplopia (P = 0.027). Treatment effect including glucocorticoid, pyridostigmine, thymectomy, IVIG, immunosuppressive drugs did not show significant difference between the relapsed and non-relapsed groups. The treatment outcome also showed no difference between the single OMG and second generalized groups. Conclusions Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months.http://link.springer.com/article/10.1186/s12883-017-0857-7Myasthenia gravisPrognosisOcularRelapse |
| spellingShingle | Lili Wang Yun Zhang Maolin He Clinical predictors for the prognosis of myasthenia gravis BMC Neurology Myasthenia gravis Prognosis Ocular Relapse |
| title | Clinical predictors for the prognosis of myasthenia gravis |
| title_full | Clinical predictors for the prognosis of myasthenia gravis |
| title_fullStr | Clinical predictors for the prognosis of myasthenia gravis |
| title_full_unstemmed | Clinical predictors for the prognosis of myasthenia gravis |
| title_short | Clinical predictors for the prognosis of myasthenia gravis |
| title_sort | clinical predictors for the prognosis of myasthenia gravis |
| topic | Myasthenia gravis Prognosis Ocular Relapse |
| url | http://link.springer.com/article/10.1186/s12883-017-0857-7 |
| work_keys_str_mv | AT liliwang clinicalpredictorsfortheprognosisofmyastheniagravis AT yunzhang clinicalpredictorsfortheprognosisofmyastheniagravis AT maolinhe clinicalpredictorsfortheprognosisofmyastheniagravis |